Frequency of De Novo Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up

BACKGROUND: Chronic hepatitis C (CHC) management has changed tremendously after direct-acting antivirals (DAAs) availability. Sustained virological response (SVR) has improved significantly, but one of the major concerns is the chances of de novo hepatocellular carcinoma (HCC) development after DAAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasool, Shahid, Hanif, Sofia, Ahmad, Aneeqa, Shafqat, Umair, Babar, Ahmad Nawaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028701/
https://www.ncbi.nlm.nih.gov/pubmed/36959987
http://dx.doi.org/10.5005/jp-journals-10018-1383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028701/
https://www.ncbi.nlm.nih.gov/pubmed/36959987
http://dx.doi.org/10.5005/jp-journals-10018-1383

Ejemplares similares